These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 17034418)

  • 1. Effect of treatment with a colloidal oatmeal lotion on the acneform eruption induced by epidermal growth factor receptor and multiple tyrosine-kinase inhibitors.
    Alexandrescu DT; Vaillant JG; Dasanu CA
    Clin Exp Dermatol; 2007 Jan; 32(1):71-4. PubMed ID: 17034418
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Facial acneiform rash associated with sorafenib.
    Fleta-Asín B; Vañó-Galván S; Ledo-Rodríguez A; Truchuelo-Díez M; Jaén-Olasolo P
    Dermatol Online J; 2009 Apr; 15(4):7. PubMed ID: 19450400
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of epidermal growth factor receptor inhibitor-induced acneiform eruption with topical recombinant human epidermal growth factor.
    Shin JU; Park JH; Cho BC; Lee JH
    Dermatology; 2012; 225(2):135-40. PubMed ID: 23006507
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cutaneous side-effects of EGFR inhibitors and their management.
    Ehmann LM; Ruzicka T; Wollenberg A
    Skin Therapy Lett; 2011 Jan; 16(1):1-3. PubMed ID: 21293833
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Classification and management of skin, hair, nail and mucosal side-effects of epidermal growth factor receptor (EGFR) inhibitors.
    Galimont-Collen AF; Vos LE; Lavrijsen AP; Ouwerkerk J; Gelderblom H
    Eur J Cancer; 2007 Mar; 43(5):845-51. PubMed ID: 17289377
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selecting patients for treatment with epidermal growth factor tyrosine kinase inhibitors.
    Bonomi PD; Buckingham L; Coon J
    Clin Cancer Res; 2007 Aug; 13(15 Pt 2):s4606-12. PubMed ID: 17671150
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum.
    Pérez-Soler R; Delord JP; Halpern A; Kelly K; Krueger J; Sureda BM; von Pawel J; Temel J; Siena S; Soulières D; Saltz L; Leyden J
    Oncologist; 2005 May; 10(5):345-56. PubMed ID: 15851793
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acneiform eruptions induced by epidermal growth factor receptor inhibitors: treatment with oral isotretinoin.
    Requena C; Llombart B; Sanmartín O
    Cutis; 2012 Aug; 90(2):77-80. PubMed ID: 22988651
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epidermal growth factor receptor inhibitors in cancer treatment: advances, challenges and opportunities.
    Modjtahedi H; Essapen S
    Anticancer Drugs; 2009 Nov; 20(10):851-5. PubMed ID: 19826350
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evidence-based treatment options for the management of skin toxicities associated with epidermal growth factor receptor inhibitors.
    Tan EH; Chan A
    Ann Pharmacother; 2009 Oct; 43(10):1658-66. PubMed ID: 19755624
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biology of interactions: antiepidermal growth factor receptor agents.
    Harari PM; Allen GW; Bonner JA
    J Clin Oncol; 2007 Sep; 25(26):4057-65. PubMed ID: 17827454
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cutaneous drug eruptions induced by sorafenib: a case series.
    Maddox JS; Kung EF; Petronic-Rosic V; Sethi A
    J Drugs Dermatol; 2008 Sep; 7(9):891-3. PubMed ID: 19112807
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Erlotinib-induced acneiform rash not affecting previously irradiated skin].
    Eguren C; Domínguez-Fernández I; Santiago-Sánchez-Mateos DI; García-Díez A
    Actas Dermosifiliogr; 2010 Mar; 101(2):186-7. PubMed ID: 20223168
    [No Abstract]   [Full Text] [Related]  

  • 14. Follicular drug eruption induced by gefitinib (ZD 1839, iressa): clinical picture correlates with in vitro data of focal epidermal necrosis after epidermal growth factor inhibition in skin cultures.
    Treudler R; Zouboulis CC
    Dermatology; 2005; 211(4):375-6. PubMed ID: 16286753
    [No Abstract]   [Full Text] [Related]  

  • 15. Grover's disease induced by cetuximab.
    Tscharner GG; Bühler S; Borner M; Hunziker T
    Dermatology; 2006; 213(1):37-9. PubMed ID: 16778425
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical approaches to minimize rash associated with EGFR inhibitors.
    Oishi K
    Oncol Nurs Forum; 2008 Jan; 35(1):103-11. PubMed ID: 18192159
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Common side effects of anti-EGFR therapy: acneform rash.
    Sipples R
    Semin Oncol Nurs; 2006 Feb; 22(1 Suppl 1):28-34. PubMed ID: 16616284
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EGFR targeting therapies: monoclonal antibodies versus tyrosine kinase inhibitors. Similarities and differences.
    Dassonville O; Bozec A; Fischel JL; Milano G
    Crit Rev Oncol Hematol; 2007 Apr; 62(1):53-61. PubMed ID: 17324578
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors.
    Wong KK; Fracasso PM; Bukowski RM; Lynch TJ; Munster PN; Shapiro GI; Jänne PA; Eder JP; Naughton MJ; Ellis MJ; Jones SF; Mekhail T; Zacharchuk C; Vermette J; Abbas R; Quinn S; Powell C; Burris HA
    Clin Cancer Res; 2009 Apr; 15(7):2552-8. PubMed ID: 19318484
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A tool for scoring of acneiform skin eruptions induced by EGF receptor inhibition.
    Wollenberg A; Moosmann N; Klein E; Katzer K
    Exp Dermatol; 2008 Sep; 17(9):790-2. PubMed ID: 18503553
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.